Hutch News

Hutch News

Stories tagged 'Marco Mielcarek'

3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant

$20M renewal of 4-decade-long federal grant to Hutch scientists

May 31, 2018 | By Susan Keown / Fred Hutch News Service

The National Cancer Institute has awarded Hutch with five years and nearly $20 million in funding for research to develop better therapies for people with blood cancers. The award is the latest renewal of a grant that has been funded continuously for more than 40 years.

View story >


Fred Hutch/SCCA transplant patient survival above the expected rate in U.S.

For 5th year in a row, bone marrow transplant program receives top recognition

Dec. 22, 2017 | By Molly McElroy

For the fifth year in a row, the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has been recognized by the Center for International Blood and Marrow Transplant Research as exceeding expectations for one-year survival rates. These survival rates specifically pertain to patients who have received transplants of blood-forming stem cells from healthy donors, a procedure pioneered at Fred Hutch.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Dec. 22, 2016

For fourth year in a row, Fred Hutch/SCCA transplant rates among best in the U.S.; immuntherapy symposium available on video for those who couldn't attend the event

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Feb. 4, 2016 | By Fred Hutch News Service staff

Drs. Marie Bleakley and Soheil Meshinchi receive $1M to design targeted immunotherapies for childhood leukemia; pancreatic cancer treatment advancing in clinical trials; novel mathematical model could transform dosage selection for clinical trials; new global initiative for breast cancer has roots in Seattle; Dr. Colin Correnti speaks at inaugural SHIFT 2016

View story >


Life with graft-vs.-host disease: When the transplant is just the beginning

How researchers are trying to combat this common, often debilitating side effect of treatment

April 21, 2015 | By Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant recipients, such as Greg Grappone, develop acute graft-vs.-host disease, which crops up within the first few months of treatment, and 40 percent get chronic GVHD, the form that appears more than 100 days post-transplant. As the name implies, the chronic condition can last for years — or a lifetime — and its symptoms range from mildly annoying to disabling to life-threatening.

View story >


Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.